MacGuire Cheswick & Tuttle Investment Counsel’s Insys Therapeutics, Inc. INSY Stock Holding History

MacGuire Cheswick & Tuttle Investment Counsel’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-10,265	Closed	-$121K	–	94
2016 Q3	$121K	Hold	10,265	–	–	0.03%	86
2016 Q2	$133K	Hold	10,265	–	–	0.03%	85
2016 Q1	$164K	Hold	10,265	–	–	0.04%	85
2015 Q4	$294K	Hold	10,265	–	–	0.07%	79
2015 Q3	$292K	Buy	10,265 +500	+5%	+$18.4K	0.07%	79
2015 Q2	$351K	Buy	9,765 +1,575	+19%	+$49.1K	0.08%	78
2015 Q1	$238K	Buy	+8,190	New	+$217K	0.05%	93
2014 Q3	–	Sell	-15,568	Closed	-$243K	–	96
2014 Q2	$243K	Hold	15,568	–	–	0.06%	87
2014 Q1	$322K	Sell	15,568 -62	-0.4%	-$1.23K	0.08%	76
2013 Q4	$202K	Buy	+15,630	New	+$217K	0.05%	95

Other funds holding INSY

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

FHAM

Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MacGuire Cheswick & Tuttle Investment Counsel's INSY Position: Q4 2016 in Review

MacGuire Cheswick & Tuttle Investment Counsel sold out of Insys Therapeutics, Inc. (INSY) in Q4 2016, closing a stake of 10,265 shares — an estimated $121K sold.

MacGuire Cheswick & Tuttle Investment Counsel first reported a position in INSY in Q4 2013 and held it in 10 quarters. The position peaked at $351K in Q2 2015. 138 funds tracked by Wall St. Rank hold INSY as of Q4 2016.

MacGuire Cheswick & Tuttle Investment Counsel reported no remaining Insys Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
MacGuire Cheswick & Tuttle Investment Counsel sold 10,265 Insys Therapeutics, Inc. shares in Q4 2016, an estimated $121K.
MacGuire Cheswick & Tuttle Investment Counsel first reported a position in Insys Therapeutics, Inc. in Q4 2013 and held it in 10 quarters.
MacGuire Cheswick & Tuttle Investment Counsel's Insys Therapeutics, Inc. position peaked at $351K in Q2 2015.
138 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2016.

Based on MacGuire Cheswick & Tuttle Investment Counsel's 13F filing for Q4 2016, filed 26 Jan 2017.